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Abstract
A single-chain Fv fragment antibody (scFv) specific for the plant hormone abscisic acid
(ABA) has been expressed in the bacterium Escherichia coli as a fusion protein. The kinet-
ics of ABA binding have been measured using surface plasmon resonance spectrometry
(BIAcore 2000) using surface and solution assays. Care was taken to calculate the concen-
tration of active protein in each sample using initial rate measurements under conditions of
partial mass transport limitation. The fusion product, parental monoclonal antibody and the
free scFv all have low nanomolar affinity constants, but there is a lower dissociation rate
constant for the parental monoclonal resulting in a three-fold greater affinity. Analogue
specificity was tested and structure-activity binding preferences measured. The biologi-
cally-active (+)-ABA enantiomer is recognised with an affinity three orders of magnitude
higher than the inactive (-)-ABA. Metabolites of ABA including phaseic acid, dihydrophaseic
acid and deoxy-ABA have affinities over 100-fold lower than that for (+)-ABA. These proper-
ties of the scFv make it suitable as a sensor domain in bioreporters specific for the naturally
occurring form of ABA.
Introduction
Antibodies can be harnessed into novel biosensors in order to study the dynamics of their anti-
gens in greater temporal and quantitative detail than has been previously possible. Many bio-
sensors have used enzymes as sensing domains because the enzyme usually has a high
specificity for substrate and the progress of the reaction can be quantified relatively easily [1].
For analytes with no accessible enzyme as bioselector, antibodies have offered an alternative
sensing domain. The versatility of the immune system to generate antibodies with high affinity
and specificity for most analytes, large and small, makes antibodies the bioselector of choice for
many applications. The monoclonal antibody hybridoma lines are immortalised and will
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continue to produce valuable antibodies, but monoclonals are expensive and, for some applica-
tions, smaller units are preferred.
Recombinant antibodies such as single chain antibodies generated from fused variable
domains (scFv) [2] are versatile tools and may be expressed in some E. coli lines in good yield.
Not all scFvs retain the activity or specificity of the parental monoclonal antibody and so, if
they are to be useful in biosensors, it is essential to test the selectivity of the scFv against the
parent immunoglobulin and to understand the kinetics of binding.
A number of monoclonal antibodies have been produced against the plant hormone abscisic
acid (ABA) including MAC 62 and its subclone MAC 252 [3–5]. These and polyclonals are
used widely to measure ABA content in plant material by radiolabelled immunoassays (RIA)
or ELISA [4, 6–8] and, increasingly, similar antibody reagents are being used as bioselectors for
biosensors [9–11]. Only one of the monoclonals has been sequenced, 15-I-C5 (GenBank
CAA82617.1) and a functional, ABA-binding scFv was previously constructed from the vari-
able domains of this monoclonal [12, 13]. When expressed in planta it is active and shown to
immunomodulate ABA activity in various plant tissues [14, 15], making it ideal for further
exploitation.
Plant hormones control growth, development and responses to changing environmental
conditions. Biosensors can report such changes in vivo and in real time, helping us to improve
our understanding of plant biology. Two biosensors for ABA have been reported recently, both
based on fusions of the plant ABA receptor protein, its interaction partner and a pair of fluores-
cent proteins to give a Förster resonance energy transfer cassette. These have affinities for ABA
ranging from around 0.1 μM [16] to 80 μM [17] and they function well in planta to report
changes in ABA concentration. However, antibodies can offer greater sensitivity (higher affin-
ity), might give options for sensor modules which do not conflict with normal receptor interac-
tions, and can be adapted for e.g. high-throughput ex vivomeasurements. Consequently, we
have examined the suitability of an anti–ABA scFv which can be readily prepared from bacte-
rial expression cultures.
Immunogloblin structure and activity depends greatly on structure-stabilising disulphide
bonds between conserved cysteine residues. The formation of these disulfide bonds usually
occurs co-translationally in the oxidising environment of the mammalian endoplasmic reticu-
lum, although they may also form in the periplasm of Gram-negative bacteria [18]. However,
protein yields from periplasmic expression are small compared to cytoplasmic expression.
Recombinant scFv expressed in the cytoplasm may not form disulfide bonds [19, 20] and tend
to aggregate as insoluble inclusion bodies of unfolded protein, but active scFv can be recovered
from cell lines carrying mutations in thioredoxin pathway genes (trxB and gor) [20]. Solubility
can also be improved by creating fusions to highly soluble partners and maltose-binding pro-
tein (MBP) in particular has been reported to act as a good folding scaffold for active scFvs in
E. coli [21–23]. The MBP fusion also facilitates purification under mild conditions. In this
paper we describe the activity and kinetics of 15-I-C5 and its derivative, MBP-antiABA-scFv,
using both heterogeneous phase (solution–solid surface) assays with a surface plasmon reso-
nance biosensor (steady-state SPR) and a homogeneous (solution) phase SPR technique using
competitive titration.
Materials and Methods
Synthetic Gene for Recombinant Antibody
The polypeptide sequence of the mouse anti-ABA scFV (GenBank CAA82617.1) was input to
DNAWorks [24] to design 40 oligonucleotides which assemble into a DNA sequence with
codon optimisation for E. coli expression (based on E. coli class II genes). A HindIII cloning
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site was added to the DNA sequence at the amino terminus, and a NotI site at the carboxy ter-
minus, of the encoded protein. The oligonucleotides were assembled by PCR [24] using high-
fidelity DNA polymerase (UltraPfu, Stratagene), and the PCR product was cloned into the Hin-
dIII and NotI sites of pBluescriptII (Stratagene). A clone with the correct DNA sequence was
confirmed by dideoxy sequencing (GenBank accession KU170610); the encoded amino acid
sequence remains identical to CAA82617.1. Additional methods are described in S1 Additional
Methods).
Using a directional cloning strategy the DNA was cloned into the pMal system (New
England Biolabs, UK) resulting in the expression of an N-terminal MBP fusion protein (MBP-
antiABA-scFv). The synthetic gene was amplified using PCR primers S1 Additional Methods
and cloned into the multiple cloning polylinker of the pMal vector. The recombinant plasmid
was transformed into DH5ά competent cells and resulting colonies were screened using blue/
white selection. Positive colonies were analysed by PCR and restriction digest for presence of
the insert. Plasmids containing an insert of the predicted size were sequenced (insert and flank-
ing vector). The recombinant vector carrying the correct sequence for antiABA scFv in-frame
with malE was transformed into Origami B, Rossetta-gami B and BL21 competent cells. The
pMal vectors use the strong Ptac promoter and themalE translation initiation signal to give
high-levels of expression and the Lac repressor gene laclq, which keeps expression low in the
absence of IPTG. The p2x version contains the intact signal sequence of themalE gene, allow-
ing the fusion proteins to be exported to the periplasmic space (S1 Fig). The c2x version has a
deletion of the signal sequence ofmalE, leading to cytoplasmic expression of the fusion protein.
Plasmids from selected recombinants containing an insert of the predicted size were sequenced
(insert and flanking vector) and correct, in-frame vector was transformed into Origami B, Ros-
setta-gami B and BL21 cell lines.
Protein Production
Cells were cultured on Rich-Broth medium with ampicillin selection (recommended in the
pMal manual) or Lysogeny broth (LB) with ampicillin + 0.4 M sucrose [25]. When cells were
cultured on Rich-Broth there was copious expression of free MBP even without induction.
When cells were cultured on LB + ampicillin + 100 mM glucose, no expression of the free MBP
could be detected in uninduced cells, indicating that 100 mM glucose was enough to suppress
expression from the tac promoter. Isopropyl β-D-1-thiogalactopyranoside (IPTG) induction
(0.05–2 mM at 16–37°C for 2–24 hours) of cells cultured on LB + ampicillin + 0.4 M sucrose
resulted in a better yield of the fusion protein. Expressed soluble proteins were harvested from
the periplasm using cold osmotic shock, cytoplasmic proteins by lysis using sonication. In each
case the scFv was purified by affinity chromatography using amylose-linked Sepharose (New
England Biolabs, UK) and elution with 10 mMmaltose. A table of yields is given in S1 Table.
Release of antiABA-scFv from the Fusion Protein
The pMal-p2x vector includes a Factor Xa protease sequence allowing the scFv to be cleaved
fromMBP after purification. The fusion protein was incubated at 20°C for 16 hours with Fac-
tor Xa (New England Biolabs, UK) and the products separated by HiTrapQ (GE Healthcare,
UK) anion exchange chromatography eluted with a gradient of NaCl (0 to 0.5 M). A linear gra-
dient resulted in poor separation (the peaks were overlapping) and so, as each protein peak
started to elute, the NaCl concentration was held until the signal returned to baseline. This
method allowed complete separation of the free scFv from both MBP and the uncleaved fusion
protein.
Anti-ABA scFv
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ABA Binding Activity
Antibody in buffer (20 mM sodium citrate, 5 mMMgSO4, pH 6.0) was mixed with 150 Bq DL-
cis,trans-[H]-abscisic acid ([3H]-(+/-)-ABA; Amersham, GE Healthcare) and 125 μg bovine γ-
globulin, +/- saturating (10−5 M) cold (+)-ABA, all in 100 μL. All assays were in triplicate.
After incubation for one hour at 4°C in darkness, three volumes of saturated ammonium sul-
phate was added followed by a further 15 min incubation on ice. Protein was pelleted by centri-
fugation, pellets rinsed carefully with saturated ammonium sulphate before solubilisation in
EcoScint scintillation fluid (National Diagnostics) and radioactivity measured by scintillation
counting (Beckman-LS6000TA).
Surface Plasmon Resonance
This study used a BIAcore 2000 (Biacore, GE Healthcare). Biacore streptavidin (SA) and car-
boxy-activated (CM5) chips, buffers and reagents were purchased from GE Healthcare, UK. If
buffers were prepared locally, they were filtered (0.2 micron) and degassed before use.
Synthesis of Biotinylated ABA
S-(+)-abscisic acid 4’-(N-succinamidyl acyl hydrazide-N’-biotinyl-3,6-dioxaoctane-1,8
diamine) (S2 Fig) and 2-cis-(R)-(+)-Abscisic acid: (2-cis-(R)-(+)-ABA) were prepared as previ-
ously described [26].
Commercial anti-ABA Monoclonal Antibodies
Monoclonal anti-ABAMAC 252 52 [3] was purchased from Abcam (product no ab50594).
Monoclonal anti-ABA 15-I-C5 [4] was purchased from Biofords Consultants SARL (Agdia,
Evry Genopole, France) as Phytodetek ABA-15-I-C5 Monoclonal Antibody.
Results and Discussion
Activity of MBP-antiABA-scFv after Expression in E. coli
Immunological reagents are widely used analytical tools. For the phytohormone ABA both
monoclonal and polyclonal reagents are available, but scFvs offer the advantages of e.g. cost-
effective, reproducible production using bacterial expression. Therefore, we developed a scFv
from the sequence of one of the widely used anti-ABA monoclonals. Some antibodies and
scFvs are compromised by expression in E. coli (e.g. [27]) and so the characteristics of the scFv
have been determined.
Expression was found to be optimal after growing cells at 37°C in the presence of 100 mM
glucose to an A600 of approximately 0.5, followed by mild and slow induction with 20 μM
IPTG in the presence of 0.4 M sucrose at 18°C for 16 hours. However, the yield of fusion pro-
tein recovered from the periplasm was low (about 0.5 mg/L; S1 Table). Cytoplasmic expression
using the pMal system usually yields considerably more protein than when the same protein is
exported into the periplasmic space, but there can be problems with folding. Nevertheless, suc-
cessful cytoplasmic expression of soluble scFvs has been reported in E. coli cells carrying muta-
tions in thioredoxin pathway genes (such as Rosetta-gami and Origami cells; 27). Recovering
both the periplasmic and cytoplasmic proteins by sonicating Rosetta-gami B cells carrying the
pAB1 plasmid yielded in excess of 20 mg/L of amylose-binding soluble fusion protein (Origami
cells 21.6 mg/L) representing about 10% of the total soluble protein.
The activity of the purified MBP-antiABA-scFv product (for brevity we will refer to this as
scFv hereafter) was assessed in a radiolabel binding assay using [3H]-(+/-)-ABA (S3 Fig). The
data showed that the scFv was active, and displayed a nanomolar affinity for free ABA at
Anti-ABA scFv
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physiological pH. Binding was found to be pH-independent between pH 5.5 and pH 8.5, but
fell off sharply below pH 5.5 as the ligand approached its pKa (pKa ABA = 4.75). For more
detailed, kinetic characterisation of the scFv, surface plasmon resonance (SPR) was used.
BIAcore Parameterisation
Instruments based on SPR such as BIAcore offer some of the most direct and reliable methods
for determining both association and dissociation kinetic rate constants [28, 29]. Ideally, in
order to minimize mass transport limitation (MTL), a low level of ligand immobilisation is
required, such as to give maximal analyte binding (Rmax) of about 100 resonance units (RU)
[30, 31]. This required loading 1 RU of the biotinylated ligand b-PEG-ABA onto an SA chip,
which proved technically challenging. As an alternative, three parallel channels of a CM5 chip
were coated with different streptavidin levels (approximately 90 RU, 550 RU and 3350 RU).
Biocytin was bound to flow cell one for use as the in-line reference, channels 2, 3 and 4 were
saturated with b-PEG-ABA. The homogeneity of the prepared surfaces was verified by moni-
toring the output from the θSPR photo-detector array.
When scFv was injected over the chip surface specific binding was observed. This binding
competed away by mixing scFv in solution with excess free ligand, 1 μM (+)-ABA. Regenera-
tion of the chip surfaces was achieved with a 1 min pulse of 50 mM NaOH. The performance
of the sensor chip surface with bound b-PEG-ABA was assessed by monitoring repeated bind-
ing and regeneration cycles. No significant build-up of protein on the chip surface or loss of
binding capacity was observed after 36 regeneration cycles.
Quantitation of the Analyte
Determination of affinity and association rate constants needs the concentration of active ana-
lyte to be known with great precision. Bacterial expression can yield both active and inactive
(unfolded etc.) scFv, and so the method developed by Christensen [32] was used to determine
the concentration of active analyte. Purified scFv (nominal protein concentration 142 nM/
10.57 μg/ml, determined by A280) was injected over channel 4 with high ligand density (Rmax
3100 RU), at several flow rates (2, 5, 10, 25, 50 and 100 μl/min). The association phase of each
sensorgram was divided into six response intervals (Fig 1). The slopes of the curves (dR/dtreg)
were determined for each response interval by linear regression at each flow rate giving low χ2
values (χ2reg) ranging between 0 and 0.21 (S2 Table). The mass transport coefficient (Lm in
ms-1) was calculated according to Eq 1.
Lm ¼ CLm
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
D2  F
h2  b  l
3
r
Equation 1
where CLm has a value of 1.21 for a BIAcore 2000 instrument with detection between 0.4 and
2.0 mm, l = 1.6 mm, D is the analyte diffusion coefﬁcient D estimated using Stoke’s law and the
Einstein-Sutherland equation, F is the ﬂow rate, h is the height of the ﬂow cell, b the width and
l the length.
The concentration of active scFv (Abulk) and the coefficient of reaction flux (Lr) were deter-
mined by globally fitting the data to Eq 2 at each flow rate, using dR/dtreg as slopes for each
response interval.
dR
dt
¼ Lm Mr  G  Lr½Abulk
Lm þ Lr
Equation 2
where R is the response level (RU) and G is a parameter that corresponds to the signal obtained
when 1 ng of protein is captured over a 1mm2 surface of the dextran matrix (1000 RUmm2ng-1).
Anti-ABA scFv
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Very good ﬁts were obtained (χ2ﬁt = 0.01–0.018). Introducing the calculated Lm, Lr and Abulk con-
centrations into Eq 2 gave simulations of ideal slopes (dR/dtﬁt), and these ﬁtted closely to the
experimental slopes (dR/dtreg) (Fig 1B). As the binding proceeds during sample injection, an
increasing number of binding sites on the chip surface become occupied, reducing the ligand den-
sity, which in turn reduces the ﬂux of the binding reaction. This is indicated by the observed
decrease of the Lr value with the later and increasing response intervals (Fig 1C).
A low variation (SD = 1.8%) of the Abulk concentrations determined in each response interval
was observed (Fig 1C) indicating that the measurements are accurate and reliable. The concentra-
tion of active scFv was calculated to be 31.0 ± 0.56 nM, the mean of the Abulk values determined in
each response interval, indicating that only 21.8% of amylose-purified MBP-antiABA-scFv was
active. This suggests that a large proportion of the protein is misfolded or damaged, but by know-
ing the concentration of active scFv it was possible to progress to kinetic assays without the need
for further purification. The same method was used to determine the concentrations of active
antibody for subsequent experiments with cleaved scFv (MBP removed) and the parental mono-
clonal 15-I-C5 (S3 Table). By way of verification, the active concentrations of selected samples
were also estimated by the method of Kazemeir [33] which gave very similar answers (S4 Fig).
Kinetic and Affinity Constants
In order to obtain reliable kinetic data we optimised the system and tested for MTL [31]. All
injections were carried out in the multichannel mode at 25°C at high flow rate (50 μl/min) and
Fig 1. Calculating the concentration of active scFv. The scFv (142 nM, as determined by measuring the
optical density at 280nm) was injected over a chip surface with high ligand immobilisation at several flow
rates. (a) The association phase of the sensorgrams was divided into six response intervals (I-VI). (b)
Comparison of the experimental (dR/dtreg) and calculated (dR/dtfit) binding rates for each response interval.
(c) Lr (red) and [Abulk] (blue) were calculated by global fitting of the data at each flow rate using Eq 2, using
dR/dtreg as slopes for each response interval. Lr values decrease with the increase of the response interval,
while the calculated [Abulk] values are contained in a small interval (30.622–32.098 nM). The calculated
concentration of active scFv is the average [Abulk] from each response interval: 30.97 ± 0.559 nM
(SD = 1.8%).
doi:10.1371/journal.pone.0152148.g001
Anti-ABA scFv
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at scFv concentrations ranging from 24 to 0.75 nM. The response from the in-line reference
(channel one), as well as the response from blank injections of buffer, were subtracted from all
sensorgrams (double referencing). The sensorgrams were globally fitted (BIAevaluation 4.1)
using a simultaneous ka/kd 1:1 Langmuir binding model (Fig 2). The residual plots show no sig-
nificant systematic deviations for the low density surface. Small deviations were observed on
medium and high ligand densities, indicating that binding was mass transport limited on these
surfaces. As a further check, the data were fitted to a 1:1 Langmuir binding model that included
a mass transport parameter (S5 Fig). Similar rate constants were obtained from fitting the data
from low density surface to both binding models (1:1 and 1:1 with MTL), suggesting that the
binding to this surface is not mass transport limited. Fitting the sensorgrams obtained on the
Fig 2. Kinetic measurements on surfaces with different ligand densities. Six concentrations of scFv
(2-fold dilutions from 24 to 0.75 nM) were injected at 25°C. The responses from the in-line reference flow cell
and blank injections were subtracted from all curves. The curves were globally fitted to a 1:1 Langmuir
binding model. For each surface density, the experimental sensorgrams (coloured lines) were overlain with
the theoretical fitted curves (black lines). In each case, the relative residual plots show the difference between
the experimental and the theoretical curves expressed as a percentage of the observed response for each
analyte concentration. The spikes observed at the beginning and the end of analyte injections are the result
of in-line reference subtraction with the slight sensorgran misalignment introduced with sequential analyte
flow in the multichannel mode. Nevertheless, residuals are mostly within 1% of Robs. The surface density,
expressed as the maximum analyte binding capacity (Rmax) was determined experimentally: Rmax 49 RU
(a); 465 RU (b); 3100 RU (c).
doi:10.1371/journal.pone.0152148.g002
Anti-ABA scFv
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medium density surface to the 1:1 binding model with MTL gave a small underestimation, but
the model failed to compensate for the much higher levels of MTL observed on the high density
surface. All the data are summarised in S4 Table.
The measured KD for this recombinant antibody purified from the periplasm is (3.6 ± 0.27)
x 10−9 M. Values calculated for Ka [(8.7 ± 0.29) x 10
5 M-1s-1] and Kd [(3.1 ± 0.06) x 10−3 s-1]
vary little between methods and values shown are from use of the Langmuir 1:1 model. Using
the same model, values for the scFv purified from the cytoplasm are similar (KD = 2.8 x 10
−9 M,
χ2 = 0.621; Ka = 9.3 ± 0.38 x 10
5 M-1s-1 and Kd = 2.6 ± 0.07 x 10
−3 s-1; S4A Table). Consequently,
we no longer treat scFv purified from periplasm and cytoplasm separately.
All heterogeneous phase (surface) techniques can be subject to artefacts introduced by
ligand immobilisation or e.g. biotinylation of the free ligand. Therefore, affinity in solution was
determined by mixing scFv (25 nM) with different concentrations of (+)-ABA (0.5, 1, 5, 10, 50,
100, 200 and 500 nM) before injection. The equilibrium mixtures (1 hour at 25°C) were
injected over an SA chip surface saturated with b-PEG-ABA at high ligand density, and the ini-
tial binding rate of free scFv was measured. The concentration of free scFv from each equilib-
rium mixture was determined from a calibration curve (S6A Fig) and plotted against the
concentration of free (+)-ABA. Data points were fitted to the solution affinity model in BIAe-
valuation (S5B Fig). A good fit (χ2 = 1.01 x 10−19) with low residuals (within ± 0.2%) gave a
solution affinity constant (KD = 3.4 x 10
−9 M) in good agreement with the value determined by
surface techniques (Table 1). Thus, the kinetics of the fusion protein have been described with
confidence. Next these were compared with the characteristics of both cleaved, free scFv and
with the parental monoclonal immunoglobulin.
Cleaved (Free) antiABA-scFv
AntiABA-scFv was successfully cleaved from the MBP fusion protein by digestion with Factor
Xa and purified by ion exchange chromatography. The active concentration of free scFv was
determined by SPR, as above, and serial dilutions (40–1.25 nM) were injected over low density
b-PEG-ABA and control channels. The sensorgrams were globally fitted to a 1:1 Langmuir
binding model (χ2 = 0.141). The kinetic constants and affinity (KD = 3.2 x 10
−9 M) were in
good agreement to values calculated for the fusion MBP-antiABA-scFv (S7 Fig, S5B Table).
The presence of the C-terminal MBP fusion protein had no measurable effect on the activity of
the scFv.
15-I-C5, the Parental Monoclonal Antibody
The binding properties of the parental monoclonal antibody (15-I-C5) were also evaluated.
Sequential injections of 2 nM 15-I-C5 were made over low density b-PEG-ABA and control
sensor chip surfaces (S7 Fig). The apparent association rate constant of 15-I-C5 was faster and
the apparent dissociation rate constant considerably slower than for the scFv. However,
Table 1. Comparing values of affinity constant determined by surface (kinetic and equilibrium) and solution (equilibrium) assays for the scFv.
Method
Parameter Kinetic analysis Steady-state binding (reverse orientation) Afﬁnity in solution
Ligand Immobilised b-PEG-ABA Immobilised MBP-aABA-scFv Free (+)-ABA
Analyte Free MBP-aABA-scFv Free b-PEG-ABA Free MBP-aABA-scFv
KD (nM) 3.55±0.27 3.70 3.37
χ2 0.19 0.065 1.01E-19
doi:10.1371/journal.pone.0152148.t001
Anti-ABA scFv
PLOS ONE | DOI:10.1371/journal.pone.0152148 March 29, 2016 8 / 14
immunogobulins are bivalent and when sensorgrams were fitted to a bivalent binding model
the calculated association immobilised b-PEG-ABA was very close to the values measured for
MBP-antiABA-rate constant for the modelled monovalent interaction between 15-I-C5 and
scFv and the free scFv (Table 2). The dissociation rate constant was about 2.5 fold slower,
resulting in a higher affinity (lower KD) for the parental immunoglobulin than the scFv.
In contrast to the direct, surface binding experiments, avidity should not affect the binding
of a small antigen in solution. The modelled kinetics were validated by testing in solution (Fig
3), as above. The affinity in solution (KD) was estimated [34] for (+)-ABA to be 1.13 nM, in
agreement with the value determined by surface binding kinetics (Table 2). The high affinities
illustrate one reason why this monoclonal became widely adopted for ABA assays from plant
tissue extracts.
Selectivity of MBP-antiABA-scFv
The selectivity of the scFv for (+)-ABA was tested by determining the affinity in solution for
structurally or physiologically related compounds. The scFv (25 nM) was mixed with different
concentrations of test compound and incubated for 1 hour at 25°C. The concentration of free
scFv in the equilibrium mixtures was determined and plotted against concentration of compet-
itor. Affinity was determined by fitting the data points to a solution affinity model (Fig 4). The
KA value was determined for each compound, and then percentage cross-reactivity was calcu-
lated by expressing each KA value relative to the KA for (+)-ABA. Values were compared to lit-
erature data for the parental monoclonal antibody (Table 3).
The scFv exhibited a high degree of selectivity for the physiologically active (+)-ABA. A
5000-fold lower cross-reactivity was observed with the optical isomer (-)-ABA, showing that
the scFv was able to distinguish sharply between the natural and unnatural (synthetic) ABA
enantiomers. Hence, it retained the strict configuration requirements at the chiral centre, posi-
tion C-1ʹ for (+)-ABA [8]. Compared to pure (+)-ABA, the cross-reactivity with racemic
(±)-ABA was a little lower (44.3%) than the anticipated 50%, most likely because the propor-
tion of the two enantiomers in the commercial mixture is not equal. Very low cross-reactivities
were observed with ABA-methyl ester (0.028%) and 1ʹ-deoxy-ABA (0.3%), suggesting that the
scFv also retained the strict structural requirements of the parental immunoglobulin for the
Table 2. Kinetic and affinity constants for 15-I-C5.
Parameter Kinetic analysis Afﬁnity in solution
1:1 Langmuir Bivalent analyte
ka1 (M
-1s-1) 3.80E+06 9.55E+05 -
SE (ka1) 2.37E+04 2.01E+05 -
kd1 (s
-1) 5.59E-06 1.18E-03 -
SE (kd1) 4.87E-06 2.95E-03 -
ka2 (s
-1) - 0.0245 -
SE (ka2) - 0.0474 -
kd2 (s
-1) - 6.61E-04 -
SE (kd2) - 1.41E-03 -
KD (M) 1.47E-12 1.23E-09* 1.13E-09
χ2 0.152 0.152 -
*The afﬁnity of the modelled monovalent component of the interaction was calculated from KD = kd1/ka1. SE, standard error based on each global ﬁt in
BIAevaluation. The sensorgrams are shown in S8 Fig.
doi:10.1371/journal.pone.0152148.t002
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Fig 3. Affinity in solution 15-I-C5.Monoclonal 15-I-C5 (5 nM) was mixed with different concentrations of (+)-ABA (0.5–500 nM) for 1 hour at 25°C. The
equilibriummixtures were injected over a sensor chip surface with high b-PEG-ABA density and the initial binding slopes were measured for each sample.
The values were plotted against the concentration of free ABA and the data points were fitted to a 4-parameter equation. KD was estimated from the
corrected inflection midpoint of the fitted curve (Stöcklein et al., 1998). The affinity in solution of 15-I-C5 for (+)-ABA was estimated to 1.13 nM.
doi:10.1371/journal.pone.0152148.g003
Fig 4. Cross-reactivity of the anti-ABA-scFv.MBP-antiABA-scFv (25 nM) was mixed with different
concentrations of each test compound for 1 hour at 25°C. The concentration of free scFv in the equilibrium
mixtures was plotted against the concentration of test compound. The structures of each competitor are
shown framed in the same colours as the data in the dose graph. There is no box for the racemic mix. The
colour code for each compound is shown on the left of the plot.
doi:10.1371/journal.pone.0152148.g004
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ABA side chain, from the C-1 to C-1ʹ and the free carboxyl group. Very low cross-reactivity
was displayed against the early catabolic product of ABA, phaseic acid (0.03%), and for the sub-
sequent catabolite dihydrophaseic acid (0.16%). Almost no cross-reactivity (lower than 10−4%)
was observed with the ABA precursor xanthoxin, benzoic acid (a control weak organic acid),
farnesol (a physiologically-related compound), lysine (a control polar amino-acid present in
the plant cell in millimolar concentrations), nor other plant hormones (auxin and gibberellic
acid).
Conclusions
Careful determination of the kinetic properties of a bacterially-expressed scFv has shown it to
retain the nanomolar KD characteristic of its parental monoclonal IgG. The values compare
favourably with a similar scFv based on 15-I-C5 and expressed in plant leaves, for which an
ELISA IC50 value of approx. 1.5 nM was estimated [13]. The selectivity of our purified, bacte-
rial scFv has been determined by quantitative assay, showing it to have a high fidelity for the
bioactive (+)-ABA enantiomer and very low cross-reactivity with structurally-related metabo-
lites. Collectively these features suggest that this antiABA-scFv is suitable for assaying this
essential hormone in plant extracts and will be an effective and reliable bioselector element for
deployment in ABA biosensors.
Supporting Information
S1 Additional Methods. Details of primers and PCR conditions.
(PDF)
Table 3. Selectivity of MBP-aABA-scFv.
Compound Afﬁnity in solution,
MBP-aABA-scFv
Cross-reactivity MBP-aABA-scFv (%) a Cross-reactivity mAb 15-I-C5 (%) b
KD (M) SE (KD) KA (M
-1)
2-cis-(S)-(+)-ABA 3.37E-09 7.43E-11 2.96E+08 100 100
2-cis-(R,S)-(±)-ABA 7.61E-09 1.08E-10 1.31E+08 44.25 49.4 d
2-cis-(R)-(-)-ABA 1.73E-05 1.36E-07 5.71E+04 0.019 0 c
2-cis-(R,S)-(±)-1’-deoxy-ABA 1.09E-06 4.29E-08 9.17E+05 0.309 n.r.
2-cis-(S)-(+)-ABA methyl ester 1.21E-05 6.04E-07 8.26E+04 0.028 <0.1 d
2-trans-(S)-(+)-ABA n.t. - - - 0 c, 0.98 d
Phaseic acid 1.13E-05 1.16E-06 8.82E+04 0.029 <0.1 c
Dihydrophaseic acid 2.17E-06 5.18E-07 4.62E+05 0.156 <0.1 c
All-trans-Farnesol 1.71E-02 5.06E-03 5.84E+01 0.00002 0 c
Xanthoxin 1.62E-03 1.09E-04 6.17E+02 0.0002 0 c
D,L-Lysine 6.12E-03 1.78E-03 1.63E+02 0.00006 n.r.
Indole-3-acetic acid 7.23E-03 9.07E-04 1.38E+02 0.00005 n.r.
Gibberellic acid 3.28E-02 1.50E-03 3.04E+01 0.00001 n.r.
Benzoic acid 1.09E-02 1.33E-03 9.17E+01 0.00003 n.r.
a Cross-reactivity was calculated using the KA value determined for each compound and assigning (+)-ABA the relative value of 100%.
b Determined by other investigators from radiolabel displacement curves using 50% displacement.
c Reported by manufacturers (Phytodetek manual m100.2, Agdia Inc., Indiana, USA).
d Walker-Simmons et al., 1991. n.t.—not tested. n.r.–not reported.
doi:10.1371/journal.pone.0152148.t003
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constants calculated for free scFv.
(PDF)
Acknowledgments
GOB was funded under EU Framework grant HPRN-CT-2002-00334 [http://ec.europa.eu/
research/fp7/index_en.cfm]. RMN appreciates the support of BBSRC Award BB/L009366
[http://www.bbsrc.ac.uk/funding/grants/]. TRS was funded by a BBSRC Biomolecular Sciences
Committee Studentship. We thank Dr Nobuhiro Hirai, Graduate School of Agriculture, Kyoto
University, Kyoto, Japan [http://www.fsao.kais.kyoto-u.ac.jp/cas/index.php?Nobuhiro%
20Hirai(en)] for samples of phaseic acid, dihydrophaseic acid and Dr Sue Abrams, Structural
Sciences Centre, University of Saskatchewan, Canada [http://www.innovation.ca/en/navigator/
SaskatchewanStructuralSciencesCentre], for the 2-cis-(R,S)-(±)-1’-deoxy-ABA. We are grateful
Anti-ABA scFv
PLOS ONE | DOI:10.1371/journal.pone.0152148 March 29, 2016 12 / 14
to Prof U Conrad for advice during the work. GOB is currently employed at PolyTherics, but
this employment started after completion of the research reported. There is no conflict of inter-
est with PolyTherics, and there has never been a financial contribution to the project. The spe-
cific roles of this author is articulated in the ‘author contributions’ section.
Author Contributions
Conceived and designed the experiments: GOB TRS AJT AM RMN. Performed the experi-
ments: GOB TRS AJT. Analyzed the data: GOB RMN. Contributed reagents/materials/analysis
tools: AM AJT RMN. Wrote the paper: GOB RMN.
References
1. Luppa PB, Sokoll LJ, Chan DW. Immunosensors—principles and applications to clinical chemistry. Clin
Chim Acta. 2001; 314: 1–26. PMID: 11718675
2. Raag R, Whitlow M. Single-chain Fvs. FASEB J. 1995; 9: 73–80. PMID: 7821762
3. Quarrie SA, Whitford PN, Appleford NEJ, Wang TL, Cook SK, Henson IE, et al. A monoclonal antibody
to (S)-abscisic acid: its characterisation and use in a radioimmunoassay for measuring abscisic acid in
crude extracts of cereal and lupin leaves. Planta. 1988; 173: 330–339. doi: 10.1007/BF00401020
PMID: 24226540
4. Mertens R, Deus-Neumann B, Weiler EW. Monoclonal antibodies for the detection and quantitation of
the endogenous plant growth regulator abscisic acid. FEBS Lett. (1983; 160: 269–272.
5. Bona CA, Kohler H. Anti-idiotype antibodies and internal images. In JC Venter, CM Fraser, J Lindstrom
Eds. Monoclonal and anti-idiotypic antibodies. Alan R Liss, New York. 1984; pp. 141–149.
6. Quarrie SA, Galfre G. Use of different hapten-protein conjugates immobilized on nitrocellulose to
screen monoclonal antibodies to abscisic acid. Anal Biochem. 1985; 151: 389–399. PMID: 2937340
7. Banowetz GM, Hess JR, Carman JG. A monoclonal antibody against the plant growth regulator,
abscisic acid. Hybridoma. 1994; 13: 537–541. PMID: 7737678
8. Walker-Simmons MK, Reaney MJT, Quarrie SA, Perata P, Vernieri P, Abrams SR. Monoclonal anti-
body recognition of abscisic acid analogs. Plant Physiol. 1991; 95: 46–51. PMID: 16667979
9. Li Y-W, Xia K, Wang R-Z, Jiang J-H, Xiao LT. An impedance immunosensor for the detection of the phy-
tohormone abscisic acid. Anal Bioanal Chem. 2010; 391: 2869–2874.
10. Li Q, Wang RZ, Huang ZG, Li HS, Xiao LT. A novel impedance immunosensor based on O-phenylene-
diamine modified gold electrode to analyze abscisic acid. Chinese ChemLett. 2010; 21: 472–475.
11. Sadanandom A, Napier RM. Biosensors in plants. Curr Opinions Plant Biol. 2010; 13: 736–743.
12. Artsaenko O, Weiler EW, Müntz K, Conrad U. Construction and functional characterization of a single
chain Fv antibody binding to the plant hormone abscisic acid. J Plant Physiol. 1994; 144: 427–429.
13. Artsaenko O, Peisker M, zur Nieden U, Fiedler U, Weiler EW, Müntz K, et al. Expression of a single
chain Fv antibody against abscisic acid creates a wilty phenotype in transgenic tobacco. Plant J. 1995;
8: 745–750. PMID: 8528285
14. Phillips J, Artsaenko O, Fiedler U, Horstmann C, Mock HP, Muentz K, et al. Seed-specific immunomo-
dulation of abscisic acid activity induces a developmental switch. EMBO J. 1997; 16: 4489–4496.
PMID: 9303293
15. Wigger J, Phillips J, Peisker M, HartungW, zur Nieden U, Artsaenko O, et al. Prevention of stomatal
closure by immunomodulation of endogenous abscisic acid and its reversion by abscisic acid treat-
ment: physiological behaviour and morphological features of tobacco stomata. Planta. 2002; 215:
413–423. PMID: 12111223
16. Waadt R, Hitomi K, Nishimura N, Hitomi C, Adams SR, Getzoff ED, et al. FRET-based reporters for the
direct visualization of abscisic acid concentration changes and distribution in Arabidopsis. eLife. 2014
3: e01739. doi: 10.7554/eLife.01739 PMID: 24737861
17. Jones AM, Danielson JÅH, ManojKumar SN, Lanquar V, Grossmann G, Frommer WB. Abscisic acid
dynamics in roots detected with genetically encoded FRET sensors. eLife. 2014; 3: e01741. doi: 10.
7554/eLife.01741 PMID: 24737862
18. Missiakas D, Raina S. Protein Folding in the Bacterial Periplasm. J. Bacteriology. 1997; 179: 2465–
2471.
19. Martineau P, Jones P, Winter G. Expression of an antibody fragment at high levels in the bacterial cyto-
plasm. J Mol Biol. 1998; 280: 117–127. PMID: 9653035
Anti-ABA scFv
PLOS ONE | DOI:10.1371/journal.pone.0152148 March 29, 2016 13 / 14
20. Messens J, Collet JF. Pathways of disulfide bond formation in Escherichia coli. Int J Biochem Cell Biol.
2006; 38: 1050–62. PMID: 16446111
21. Hayhurst A. Improved expression characteristics of single-chain Fv fragments when fused downstream
of the Escherichia coli maltose-binding protein or upstream of a single immunoglobulin-constant
domain. Protein Expression and Purification. 2000; 18: 1–10. PMID: 10648163
22. Shaki-Loewensteina S, Zfaniaa R, Hylandb S, WelsbWS, Benhara I. A universal strategy for stable
intracellular antibodies. J Immun Methods. 2005; 303: 19–39.
23. Wörn A, Plückthun A. Stability engineering of antibody single-chain Fv fragments. J Mol Biol. 2001;
305: 989–1010. PMID: 11162109
24. Hoover DM, Lubkowski J. DNAWorks: an automated method for designing oligonucleotides for PCR-
based gene synthesis. Nucleic Acids Res. 2002; 30: e43. doi: 10.1093/nar/30.10.e43 PMID: 12000848
25. Kipriyanova SM, Moldenhauerb G, Littlea M. High level production of soluble single chain antibodies in
small-scale Escherichia coli cultures. J Immun Methods. 1997; 200: 69–77.
26. Smith TR, Clark AJ, Napier RM, Taylor PC, Thompson AJ, Marsh A. Function and stability of abscisic
acid hydrazone conjugates by LC-MS2 of ex vivo samples. Bioconjugate Chem. 2007; 18: 1355–1359.
27. Jurado P, Ritz D, Beckwith J, de Lorenzo V, Fernandez LA. Production of functional single-chain Fv
antibodies in the cytoplasm of Escherichia coli. J Mol Biol. 2002; 320: 1–10. PMID: 12079330
28. Jönsson UL, Fagerstam B, Ivarsson B, Johnsson R, Karlsson K, Lundh S, et al. Real-time biospecific
interaction analysis using surface plasmon resonance and a sensor chip technology. BioTechniques.
1991; 11: 620–627. PMID: 1804254
29. Malmqvist M. Surface plasmon resonance for detection and measurement of antibody-antigen affinity
and kinetics. Curr Opin Immunol. 1993; 5: 282–286. PMID: 8507407
30. Myszka DG. Kinetic analysis of macromolecular interactions using surface plasmon resonance biosen-
sors. Curr Opin Biotechnol. 1997; 8: 50–57. PMID: 9013659
31. Myszka DG, He X, Dembo M, Morton Thomas A, Goldstein B. Extending the Range of Rate Constants
Available from BIACORE: Interpreting Mass Transport-Influenced Binding Data. Biophys J. 1998; 75:
583–594. PMID: 9675161
32. Christensen LLH. Theoretical analysis of protein concentration determination using biosensor technol-
ogy under conditions of partial mass transport limitation. Anal Biochem. 1997; 249: 153–164. PMID:
9212867
33. Kazemier B, De Haard H, Boender P, Van Gemen B, HoogenboomH. Determination of active single
chain antibody concentrations in crude periplasmic fractions. J Immun Methods. 1996; 194: 201–209.
34. Stöcklein WFM,Warsinke A, Micheel B, Kempter G, HöhneW, Scheller FW. Diphenylurea hapten
sensing with a monoclonal antibody and its fab fragment: Kinetic and thermodynamic investigations.
Anal Chim Acta. 1998; 362: 101–111.
Anti-ABA scFv
PLOS ONE | DOI:10.1371/journal.pone.0152148 March 29, 2016 14 / 14
